Xu S - Search Results

1

Resveratrol and endothelial function: A literature review.

Parsamanesh N, Asghari A, Sardari S, Tasbandi A, Jamialahmadi T, Xu S, Sahebkar A. Parsamanesh N, et al. Among authors: xu s. Pharmacol Res. 2021 Aug;170:105725. doi: 10.1016/j.phrs.2021.105725. Epub 2021 Jun 10. Pharmacol Res. 2021. PMID: 34119624 Review.

2

Targeting mTORs by omega-3 fatty acids: A possible novel therapeutic strategy for neurodegeneration?

Shirooie S, Nabavi SF, Dehpour AR, Belwal T, Habtemariam S, Argüelles S, Sureda A, Daglia M, Tomczyk M, Sobarzo-Sanchez E, Xu S, Nabavi SM. Shirooie S, et al. Among authors: xu s. Pharmacol Res. 2018 Sep;135:37-48. doi: 10.1016/j.phrs.2018.07.004. Epub 2018 Jul 7. Pharmacol Res. 2018. PMID: 29990625 Review.

3

Danhong injection in cardiovascular and cerebrovascular diseases: Pharmacological actions, molecular mechanisms, and therapeutic potential.

Feng X, Li Y, Wang Y, Li L, Little PJ, Xu SW, Liu S. Feng X, et al. Among authors: xu sw. Pharmacol Res. 2019 Jan;139:62-75. doi: 10.1016/j.phrs.2018.11.006. Epub 2018 Nov 5. Pharmacol Res. 2019. PMID: 30408571 Review.

4

Cryptotanshinone protects against pulmonary fibrosis through inhibiting Smad and STAT3 signaling pathways.

Zhang Y, Lu W, Zhang X, Lu J, Xu S, Chen S, Zhong Z, Zhou T, Wang Q, Chen J, Liu P. Zhang Y, et al. Among authors: xu s. Pharmacol Res. 2019 Sep;147:104307. doi: 10.1016/j.phrs.2019.104307. Epub 2019 Jun 7. Pharmacol Res. 2019. PMID: 31181334

5

Targeting BDNF signaling by natural products: Novel synaptic repair therapeutics for neurodegeneration and behavior disorders.

Bawari S, Tewari D, Argüelles S, Sah AN, Nabavi SF, Xu S, Vacca RA, Nabavi SM, Shirooie S. Bawari S, et al. Among authors: xu s. Pharmacol Res. 2019 Oct;148:104458. doi: 10.1016/j.phrs.2019.104458. Epub 2019 Sep 20. Pharmacol Res. 2019. PMID: 31546015 Review.

6

Therapeutic potential of polyphenols in cardiovascular diseases: Regulation of mTOR signaling pathway.

Sanches-Silva A, Testai L, Nabavi SF, Battino M, Pandima Devi K, Tejada S, Sureda A, Xu S, Yousefi B, Majidinia M, Russo GL, Efferth T, Nabavi SM, Farzaei MH. Sanches-Silva A, et al. Among authors: xu s. Pharmacol Res. 2020 Feb;152:104626. doi: 10.1016/j.phrs.2019.104626. Epub 2020 Jan 2. Pharmacol Res. 2020. PMID: 31904507 Review.

7

Therapeutic potential of blood flow mimetic compounds in preventing endothelial dysfunction and atherosclerosis.

Xu S. Xu S. Pharmacol Res. 2020 May;155:104737. doi: 10.1016/j.phrs.2020.104737. Epub 2020 Feb 29. Pharmacol Res. 2020. PMID: 32126273 Review.

8

Epigenetics in atherosclerosis: key features and therapeutic implications.

Carbone F, Montecucco F, Xu S, Banach M, Jamialahmadi T, Sahebkar A. Carbone F, et al. Among authors: xu s. Expert Opin Ther Targets. 2020 Aug;24(8):719-721. doi: 10.1080/14728222.2020.1764535. Epub 2020 Jun 1. Expert Opin Ther Targets. 2020. PMID: 32354276 No abstract available.

9

COVID-19 and Kawasaki disease in children.

Xu S, Chen M, Weng J. Xu S, et al. Pharmacol Res. 2020 Sep;159:104951. doi: 10.1016/j.phrs.2020.104951. Epub 2020 May 25. Pharmacol Res. 2020. PMID: 32464327 Free PMC article. No abstract available.

10

Cyclodextrins: Potential therapeutics against atherosclerosis.

Mahjoubin-Tehran M, Kovanen PT, Xu S, Jamialahmadi T, Sahebkar A. Mahjoubin-Tehran M, et al. Among authors: xu s. Pharmacol Ther. 2020 Oct;214:107620. doi: 10.1016/j.pharmthera.2020.107620. Epub 2020 Jun 26. Pharmacol Ther. 2020. PMID: 32599008 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

24,720 results

Search Page